New innovators with jane king interview with jaguar health ceo lisa conte spotlights company's near-term commercial & development milestones

Click here to view interview video paramount near-term activities include planned october 2024 commercial launch of fda-approved oral mucositis prescription product gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases san francisco, ca / accesswire / september 4, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that a new innovators with jane king video interview of lisa conte, jaguar's founder, president, and ceo, is available and can be viewed by clicking here . "our paramount near-term activities are our planned october 2024 commercial launch of the fda-approved oral mucositis prescription product gelclair in the u.s. and progressing our rare disease development business," said conte.
JAGX Ratings Summary
JAGX Quant Ranking